Skip to Main content Skip to Navigation
Journal articles

[Future drug targets for Parkinson's disease].

Abstract : Parkinson's disease is characterized by a triad of cardinal motor symptoms (bradykinesia, rigidity and tremor) resulting from the loss of dopaminergic neurons in the substantia nigra. This synucleinopathy is classified in the larger group of Lewy body disorders. Currently, these symptoms are relatively well alleviated by drugs that restore dopaminergic neurotransmission, andlor by deep brain stimulation. It is not yet possible to halt the underlying degeneration, or to treat symptoms due to non-dopaminergic neuron damage. This review examines the mechanisms of neuronal degeneration in Parkinson's disease, new targets for neuroprotection, and the mechanisms causing symptoms resistant to current treatments.
Document type :
Journal articles
Complete list of metadata

Cited literature [18 references]  Display  Hide  Download
Contributor : Farid Aouinat Connect in order to contact the contributor
Submitted on : Wednesday, August 7, 2013 - 12:36:23 PM
Last modification on : Sunday, June 26, 2022 - 9:40:51 AM
Long-term archiving on: : Friday, November 8, 2013 - 4:22:46 AM


Files produced by the author(s)


  • HAL Id : inserm-00850568, version 1
  • PUBMED : 23815021


Etienne C. Hirsch. [Future drug targets for Parkinson's disease].. Bulletin de l'Académie Nationale de Médecine, Elsevier Masson, 2012, 196 (7), pp.1369-77; discussion 1377-9. ⟨inserm-00850568⟩



Record views


Files downloads